Sugi Predict

Sugi Predict / Targets / PPIB

PPIB

Peptidyl-prolyl cis-trans isomerase B · P23284 · PPIB on Sugi Atlas →

7,019 patent compounds predicted against PPIB, 5,069 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL954750 SCHEMBL954750 0.74 19/20
SCHEMBL954752 SCHEMBL954752 0.74 19/20
SCHEMBL953003 SCHEMBL953003 0.76 18/20
SCHEMBL953004 SCHEMBL953004 0.76 18/20
SCHEMBL3754684 SCHEMBL3754684 0.75 18/20
SCHEMBL3754690 SCHEMBL3754690 0.75 18/20
SCHEMBL953426 SCHEMBL953426 0.72 18/20
SCHEMBL953429 SCHEMBL953429 0.72 18/20
SCHEMBL954309 SCHEMBL954309 0.69 18/20
SCHEMBL954311 SCHEMBL954311 0.69 18/20
SCHEMBL954312 SCHEMBL954312 0.69 18/20
SCHEMBL1708985 SCHEMBL1708985 0.76 17/20
SCHEMBL958035 SCHEMBL958035 0.75 17/20
SCHEMBL958036 SCHEMBL958036 0.75 17/20
SCHEMBL952402 SCHEMBL952402 0.73 17/20
SCHEMBL952403 SCHEMBL952403 0.73 17/20
SCHEMBL954002 SCHEMBL954002 0.69 17/20
SCHEMBL954003 SCHEMBL954003 0.69 17/20
SCHEMBL956366 SCHEMBL956366 0.66 17/20
SCHEMBL956367 SCHEMBL956367 0.66 17/20

Clinical trials — most relevant to PPIB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding PHASE4NOT_YET_RECRUITING
IMPROVEMENT in ERADICATION of H-PYLORI INFECTION PHASE4COMPLETED
Neuro-immune Interactions and PPI PHASE4COMPLETED
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia PHASE3COMPLETED
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. PHASE1/PHASE2COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Effectiveness of Physiologic Testing in PPI Non-Responders EARLY_PHASE1COMPLETED
Identification of Acute Intermittent Porphyria Modifying Genes nanRECRUITING
Portable Measurement of Protoporphyrin IX in the Skin nanCOMPLETED
Studies in Porphyria I: Characterization of Enzyme Defects nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing nanCOMPLETED
Evaluating Changes in Skeletal Muscle Proteins Following Resistance Exercise and Single-Leg Disuse nanCOMPLETED
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
Expression of Markers Related to Mitochondrial Functionality in Carcinoma of the Urinary Bladder: Comparative Retrospective Analysis Between Recurrent Tumors (Non-responders) and Non-recurrent Tumors (Responders) After Intravesical Treatment With Chemotherapy or Immunotherapy nanUNKNOWN
Parkinson's Diseases Susceptibility Genes and Pesticides nanCOMPLETED
Peripheral Perfusion Index in Acute Surgical Patients nanCOMPLETED
Regulation of Mucosal Healing in Inflammatory Bowel Disease nanRECRUITING
FKBP5 Methylation and Childhood Emotional Abuse in Complex Posttraumatic Stress Disorder: Investigating the Relationship and Its Predictive Role in Therapy Outcome nanCOMPLETED
Cerebellar Mutism Syndrome Study nanRECRUITING
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease nanCOMPLETED
Longitudinal Study of the Porphyrias nanRECRUITING
Clinical Diagnosis of Acute Porphyria nanCOMPLETED
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B) nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Adiposity and Immunometabolism in Sepsis nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPIB binder may also engage these)

ProteinNameSimilarity
P80311 — 1.000 P80311 →
P24368 — 0.997 P24368 →
P24369 — 0.996 P24369 →
P24367 — 0.990 P24367 →
P52013 — 0.988 P52013 →
B3A0R0 — 0.987 B3A0R0 →
P0CP79 — 0.986 P0CP79 →
Q26994 — 0.986 Q26994 →
Q0P5D0 — 0.985 Q0P5D0 →
Q4I5R9 — 0.985 Q4I5R9 →
O49605 — 0.984 O49605 →
P30412 — 0.984 P30412 →
Q8X166 — 0.984 Q8X166 →
Q27774 — 0.984 Q27774 →
P0C1I0 — 0.984 P0C1I0 →
Q9ZVJ4 — 0.984 Q9ZVJ4 →
P0CP78 — 0.984 P0CP78 →
Q9D0W5 — 0.984 Q9D0W5 →
Q9SP02 — 0.983 Q9SP02 →
Q5B4R3 — 0.983 Q5B4R3 →
P0C1H9 — 0.983 P0C1H9 →
P52018 — 0.983 P52018 →
D4AY02 — 0.982 D4AY02 →
Q7S7Z6 — 0.982 Q7S7Z6 →
Q8SRE1 — 0.982 Q8SRE1 →
PPIL1 Peptidyl-prolyl cis-trans isomerase-like 1 0.982 landscape →
PPIC Peptidyl-prolyl cis-trans isomerase C 0.982 landscape →
P23285 — 0.982 P23285 →
PPIH Peptidyl-prolyl cis-trans isomerase H 0.982 landscape →
P52014 — 0.981 P52014 →